Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes

Journal Paper/Review - Aug 1, 2016


Xin B, Groll M, Driessen C, van der Stelt M, Kisselev A, van der Marel G, Filippov D, Florea B, Besse A, Huber E, de Bruin G, Overkleeft H. Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes. J Med Chem 2016; 59:7177-87.
Journal Paper/Review (English)
J Med Chem 2016; 59
Publication Date
Aug 1, 2016
Issn Electronic
Brief description/objective

This work reports the development of highly potent and selective inhibitors of the β5c catalytic activity of human constitutive proteasomes. The work describes the design principles, large hydrophobic P3 residue and small hydrophobic P1 residue, that led to the synthesis of a panel of peptide epoxyketones; their evaluation and the selection of the most promising compounds for further analyses. Structure-activity relationships detail how in a logical order the β1c/i, β2c/i, and β5i activities became resistant to inhibition as compounds were diversified stepwise. The most effective compounds were obtained as a mixture of cis- and trans-biscyclohexyl isomers, and enantioselective synthesis resolved this issue. Studies on yeast proteasome structures complexed with some of the compounds provide a rationale for the potency and specificity. Substitution of the N-terminus in the most potent compound for a more soluble equivalent led to a cell-permeable molecule that selectively and efficiently blocks β5c in cells expressing both constitutive proteasomes and immunoproteasomes.